Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 327-336

  Darbà, Josep ^a   Pérez Álvarez, Nuria ^b   Kaskens, Lisette ^b   Holgado Pérez, Susana ^c   Racketa, Jill ^d   Rejas, Javier ^d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b BCN Health Economics and Outcomes Research   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d PFIZER INC   (United States)

Author keywords

Bazedoxifene; Costs; Efficacy; Fracture; Nonvertebral; Osteoporosis; Raloxifene; Vertebral

Indexed keywords

BAZEDOXIFENE; HEPARIN; PLACEBO; RALOXIFENE; WARFARIN;

ADULT; AGED; ARTICLE; BREAST CYST; COHORT ANALYSIS; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FIBROCYSTIC BREAST DISEASE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SPAIN; SPINE FRACTURE; STATISTICAL MODEL;

EID: 84880092979     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S42755     Document Type: Article

References (54)

1. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
2. Koda-Kimble MA, Young LY, Alldredge BK, et al. Applied Therapeutics Clinical Use of Drugs, 9th ed. Philadelphia, PA: Wolters Kluwer Health/ Lippincott Williams & Wilkins; 2009.
3. Sosa M, Gómez de Tejada MJ, Hernández Hernández D. Concepto, clasificación, factores de riesgo y clínica de la osteoporosis. [Concept, classification, risk factors and clinics of osteoporosis]. Rev Esp Enf Metab Oseas. 2001;10:7-11. Spanish.
4. Melton LJ III, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int. 1999;10:214-221.
5. Bouza C, López T, Palma M, Amate JM. Hospitalised osteoporotic vertebral fractures in Spain: analysis of the national hospital discharge registry. Osteoporos Int. 2007;18:649-657.
6. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2:285-289.
7. Sociedad Española de Investigaciones Óseas y Metabolismo Mineral (SEIOMM) Osteoporosis postmenopáusica. Guía de práctica clínica. [Spanish Society for Bone Research and Mineral Metabolism. Postmenopausal osteoporosis. Clinical practice guideline] 2003. Rev Clin Esp. 2003;203(10):496-506.
8. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213.
9. Lewiecki EM. Emerging drugs for postmenopausal osteoporosis. Expert Opin Emerg Drugs. 2009;14:129-144.
10. Ettinger B, Black DM, Mitlak BH, et al; for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
11. Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother. 2002;3:681-691.
12. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23:525-535.
13. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause. 2009;16:1102-1108.
14. Silverman SL, Christiansen C, Genant HK, et al. Eff icacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23: 1923-1934.
15. de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int. 2011;22:567-576.
16. Del Pino Montes J. Epidemiología de las fracturas osteoporóticas: las fracturas vertebrales y no vertebrales. [Epidemiology of osteoporotic fractures: Vertebral fractures and non-vertebral fractures]. Rev Osteoporos Metab Miner. 2010;2:S8-S12. Spanish.
17. Strom O, Borgstrom F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int. 2007;18:1047-1061.
18. Borgstrom F, Strom O, Kleman M, et al. Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int. 2011;22:955-965.
19. Instituto de Salud Carlos III, Análisis coste-utilidad de los tratamientos farmacológicos para la prevención de fracturas en mujeres con osteoporosis en ESPAÑA. [Cost-utility analysis of pharmaceutical treatments for the prevention of fractures in women with osteoporoisis in Spain]. Informe Público de Evaluación de Tecnologías Sanitarias IPE 63/2010 [Public report for the Evaluation of Health Technologies IPE 63/2010]. Available from: http://www.isciii.es/htdocs/publicaciones/documentos/63. Accessed May 13, 2011. Spanish.
20. Darba J, Restovic G, Kaskens L, et al. Patient preferences for osteoporosis in Spain: a discrete choice experiment. Osteoporos Int. 2011;22:1947-1954.
21. Sanfelix-Genoves J, Peiro S, Sanfelix-Gimeno G, et al. Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study. BMC Public Health. 2010;10:153.
22. Ismail AA, Pye SR, Cockerill WC, et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int. 2002;13:565-571.
23. Felsenberg D, Silman AJ, Lunt M, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res. 2002;17:716-724.
24. Marín F, Gonzalez-Macias J, Moya R, et al. Fragility nonspinal fractures in a cohort of 5,201 women aged 65 years and older during a 3-year follow-up. Med Clin (Barc). 2006;127:401-404. Spanish.
25. Ministerio de Sanidad, Política Social e Igualdad (MSPI), Series 1981-2007: Mortalidad por causa de muerte, España y comunidades autónomas. [Series 1981-2007: Mortality by mortality cause, Spain and Autonomous Regions]. Available from: http://www.msc.es/estadEstudios/estadisticas/estadisticas/estMinisterio/mortalidad/seriesTablas.htm. Accessed April 26, 2011. Spanish.
26. Agència d́Informació, Avaluació i Qualitat en Salut. Guía de Práctica Clínica sobre Osteoporosis y Prevención de Fracturas por Fragilidad. 2010. Guías de Práctica Clínica en el SNS: AATRM No 2007/02. [Agency of Information, Evaluation and Quality in Health. Clinical practice guideline on osteoporosis and prevention of fragility fractures. 2010. Clinical guidelines of the NHS: AATRM No 2007/02]. Available from: http://www.gencat.cat/salut/depsan/units/aatrm/pdf/gpc_osteoporosi_aatrm2010_vcompleta.pdf. Accessed May 13, 2011. Spanish.
27. Sociedad Navarra de Medicina de Familia y Atención Primaria. Documento para el Manejo de la Osteoporosis en Atención Primaria (Actualización Diciembre 2006). [Navarran Society of Family Medicine and Primary Care. Report for the management of osteoporosis in Primary Care (updated December 2006)]. Available from: http://www.guiasalud.es/GPC/GPC_363.pdf. Accessed April 29, 2011. Spanish.
28. Adachi JD, Adami S, Gehlbach S, et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc. 2010;85:806-813.
29. Sobocki P, Lekander I, Borgstrom F, Strom O, Runeson B. The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry. 2007;22:146-152.
30. Zethraeus N, Borgstrom F, Jonsson B, Kanis J. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. Int J Technol Assess Health Care. 2005;21:433-441.
31. Pinto JL, Sanchez F, Métodos para la evaluación económica de nuevas prestaciones. [Methods for the economic evaluation of new services]. Editado por: Centre de Recerca en Economía i Salut Cres y Ministerio de Sanidad y Consumo, España [Edited by: Centre for Economics and Health - Cres and Ministry of Health and Consumption, Spain]. Available from: http://www.msc.es. Accessed April 29, 2011. Spanish
32. Vademecum.es. [Drug cost database]. Available from: http://www.vademecum.es/. Accessed April 29, 2011. Spanish.
33. Borgstrom F, Jonsson B, Strom O, Kanis JA. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. [Methods for the economic evaluation of new services]. Osteoporos Int. 2006;17:1781-1793.
34. Jonsson B, Christiansen C, Johnell O, Hedbrandt J. Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int. 1995;5:136-142.
35. Sacristán JA, Oliva J, del Llano J, Prieto L, Pinto JL. What is an efficient health technology in Spain?. Gac Sanit. 2002;16:334-343. Spanish.
36. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189-2197.
37. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104:837-844.
38. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-137.
39. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727-2741.
40. Zethraeus N, Johannesson M, Jonsson B. A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care. 1999;15:352-365.
41. Ziller V, Wetzel K, Kyvernitakis I, Seker-Pektas B, Hadji P. Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climacteric. 2011;14:228-235.
42. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-1022.
43. Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int. 2003;14: 808-813.
44. Jonsson B, Strom O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22:967-982.
45. Christodoulou C, Cooper C. What is osteoporosis? Postgrad Med J. 2003;79:133-138.
46. Naves M, az-Lopez JB, Gomez C, Rodriguez-Rebollar A, Rodriguez-Garcia M, Cannata-Andia JB. The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int. 2003;14:520-524.
47. Hospital Lluís Alcanyis, Memoria 2000. [Lluís Alcanyis hospital, Note 2000]. Available from: http://www.ctv.es/USERS/vgisbertj/home.html. Accessed May 3, 2011. Spanish.
48. Hospital de la Esperanza, Tarifario 1995, Hospital de la Esperanza, Barcelona, 1995. [Esperanza Hospital, Tariffs 1995 of Hospital Esperanza, 1995]. Spanish.
49. Instituto Nacional de la Salud, Resultados de la gestión analítica en los hospitales del INSALUD GECLIF 2000. [National Health Institute, Results of the analytical management in hospitals of INSALUD GECLIF 2000] Subdirección General de Coordinación Administrativa, Hospitales INSALUD, Madrid, 2001. Spanish.
50. Finnern HW, Sykes DP. The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos Int. 2003;14:429-436.
51. Cernuda C. Coste de consultas externas: visitas y pruebas. [Costs of external visits: visits and tests]. Todo Hospital, no 153 Enero/Febrero, 1999, H. Universitario Josep Trueta, Girona, 1999. Spanish.
52. Diari Oficial de la Generalitat de Catalunya. Departament de Sanitat i Seguretat Social. Orden de 29 de Septiembre de 1997; núm. 2504. [Official Journal of the Generality of Catalonia. Department of Health and Social Security. Order of 29th of September 1997]. Spanish.
53. Diari Oficial de la Generalitat de Catalunya. Institut Català de la Salut. Departament de Salut. RESOLUCIÓN SLT/383/2009, de 21 de enero, sobre la revisión de precios públicos correspondientes a los servicios sanitarios que presta el Instituto Catalán de la Salud. [Official Journal of the Generality of Catalonia. Catalonian department of health. Department of Health. Resolution SLT/383/2009, 21st of January, concerning the review of public tariffs corresponding to health services by the Catalan Health Institute]. Febrero 2009; núm. 5325. Available from: https://www.gencat.cat/eadop/imagenes/5325/09042029.pdf. Accessed March 3, 2011. Spanish.
54. Boletín Oficial De La Rioja. Consejería de Salud. Resolución del Consejero de Salud por la que se dispone la publicación de las tarifas por servicios sanitarios prestados a particulares en los centros del Servicio Riojano de Salud. [Official Journal of the Rioja. Health council. Resolution by the health council by which it disposes over the publication of tariffs for health services to patients in Riojan health centers]. Febrero 2009; núm. 27. Available from: http://www2.larioja.org/pls/dad_user/G04.texto_integro?p_cdi_accn=443-230928. Accessed March 3, 2011. Spanish.